AiCure is an AI and advanced data analytics company targeting the healthcare industry.
AiCure uses artificial intelligence to see, hear and understand how people respond to treatment across clinical trials and patient care.
AiCure was founded in 2010 by Adam Hanina, Gordon Kessler, & Laura Shafner. The company is based in New York, New York, with offices in London, New Jersey, and San Francisco.
AiCure's proprietary intelligent software captures and understands video, audio, and behavioral data to establish the link between patients, disease and treatment.
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials.
AiCure’s value is structured around four key pillars: data integrity; lower variability; predictive composite measures; and increases in statistical power. Incorporating these data pillars into study design allows for faster, smaller trials.
AiCure is enabling intelligent decision-making and improving health outcomes. The company has more than 100 patents filed and works with global clients in over 25 countries.
AiCure is backed by Baird Capital, Palisades Growth Capital (PGC), Silicon Valley Bank (SVB), Singtel Innov8 (Innov8), New Leaf Venture Partners and others. The company raised $24.5M from a "Series C" financing on Nov 07, 2019. This new round brings AiCure's total funding to $51.8M to date.
AiCure was recognized as one of the world's 100 most innovative artificial intelligence companies, a recipient of the Scrip Award, and Digital Health 150.